Genzyme unveiled new disability data from the Care MS II Phase III head-to-head trial of its CD52-targeting antibody, Lemtrada (alemtuzumab), which confirmed its superiority over Rebif (interferon beta-1a) in patients with relapsing-remitting multiple sclerosis (MS) who had relapsed on prior therapy.